Camurus AB is a pharmaceutical company in Sweden focused on research and development. Specializing in developing treatments for serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. With a medium risk rating score of 21.8, Camurus AB's innovative products in their clinical pipeline, including CAM2029, CAM4072, and CAM2043, are developed both in-house and in collaboration with international pharmaceutical companies. Their dedication to ESG principles sets them apart in the industry.